F om [illegible] Shan [illegible]
To [illegible]
Subje t Re Eme g ng Mic bes & Infect ons - TEMI-20 0-0121 - changes qui ed o ou subm s ion
Date iday eb ua y 4 2020 6 13 2 M

I just finished reading Feng's paper – indeed ery good.

Small e ror noted in he f rst paragraph "Know ng he origin of such a pa hogen is critical to de clop ng means to blocking further transm ssion and to de clop accines". I saw this kind of error frequent for asian people but no big deal.

Feng Gao s my 师兄 in 北京的病毒所 we we e from the same lab where my former director has now been infec ed by SARS CoV 2! Ve y sad but he s doing OK!

Shan-Lu

From Lu, Shan Shan.Lu@umassmed.edu>
Date F iday, Feb ua y 14, 2020 at 5 10 PM
To Shan-Lu L u lu.6244@osu.edu>, Su, Lishan l shan_su@med.unc.edu>
Sub ect RE Eme ging Mic obes & Infections - TEMI-2020 0121 - changes equi ed to you subm ssion

I don t have any objec ion. I see the point o add mo e cond tions to make su e the commen a y does not exclude ce tain a e o unusual s tua ions. At the same time, the mo e wet y to be comple e (o mo e like a lawye), it may gene ate mo e ques ions o even suppo t some people to say see these big name autho s also ag ee the e a e possib l ties of this and that...

Th s is the same eason of t ying o be simple and focused o avoid cove ing compl cated ssues. I don t know how to solve this conflict between be ng tho ough and avoiding confus on. I will ok to take anything once you wo had ca eful thought.

At the same time, I w ll fo wa d to you the comment f om one Biotech ch ef afte l d st ibuted Feng Gao s pape th s mo ning. It was quite su p sing to me and it shows how d ve sity of the po ent al eade s. We can only t y to do ou best.

Shan

F om Liu, Shan-Lu l u 6244@osu.edu>
Sent F iday, Feb ua y 14, 2020 2 19 PM
To Su, L shan l shan_su@med.unc.edu>, Lu, Shan Shan.Lu@umassmed.edu>
Subject Re Eme g ng Mic obes & Infect ons - TEMI-2020 0121 - changes equi ed to you submiss on

L shan: ooks good o me.
Shan: what do you think?

Thanks.

From Su, L shan [l h @]>
Date F iday, Feb ua y 14, 2020 at 1 34 PM
To Shan-Lu L u lu.6244@osu.edu>, Lu, Shan shan.lu@umassmed.edu>
Sub ect Re Eme ging Mic obes & Infections - TEMI-2020 0121 - changes equi ed to you subm ssion

How about this?

-L shan

From L u, Shan-Lu lu.6244@osu.edu>
Date F iday, Feb ua y 14, 2020 at 12 47 PM
To Su, L shan [l h @]>, Lu, Shan [h l @]>
Sub ect Re Eme ging Mic obes & Infections - TEMI-2020 0121 - changes equi ed to you subm ssion

Lishan

I get you point – maybe below one eads bet e ?

"We should emphas ze that, although SARS-CoV-2 shows no evidence of labo ato y o ign, w uses e th such g eat public health th eats must be handled p ope ly in the labo ato y and also p ope ly egulated by scien tific commun ty and gove nments."

Thoughts?

Shan-Lu Liu, M.D., Ph D.
P ofesso
Co-Di ecto , Vi uses and Eme ging Pathogens P og am
Infectious Diseases Inst tu e
Cente fo Ret ovi us Resea ch
Depa ments of Ve e na y Biociences, Mic obial Infection and Immunity, and M c ob ology
The Oh o State Un ve s ty
1900 Co lev Rd, Room 480 VMAB
Columbu , Oh o 43210
Phone (614) 292-8690
Fax (614) 292-6473
Ema l Lu.6244@osu.edu shan.lu.lu@osumc.edu

On 2/14/20, 11 08 AM, Su, Lishan l shan_su@med.unc.edu> w ote

How about adding the last sentence n the p ood?

Evolution s stepwise and acc ues mutations g adually ove t me, whe eas synthet c consit uc s would typica ly use a known backbone and nt oduce logical o ta geted changes instead of the andomly occu ing mutations that a e p esent in natu ally sola ed vi uses such as bat CoV RaTG13. In ou view, the e is cu ently no c ed ble evidence to uppo t the cla m that SARS CoV 2 o iginated f om a labo ato y-eng nee ed CoV. It is mo e l kely that SARS-CoV-2 is a ecomb nant CoV gene ated in natu e be ween a bat CoV and anothe co ceivi us in an ntie mediate animal hos . Mo e studies a e needed to explo e th s possibility and evolve the natu al o g n of SARS CoV-2. Although the SARS2 CoV has shown no evidence of labo ato y o igin, it is impo tant to point out that such vi uses in the labo ato y as d scussed he e do pose public health conce ns and should be ca efu ly moni o ed and egulated.

-Lishan

--- O ig nal Message- ---
F om Liu, Shan-Lu [l.6244@]>
Date Thu sday, Feb ua y 13, 2020 at 10 04 AM
To Lu, Shan shan.lu@umassmed.edu>
Cc Su, Lishan [l.h @]>
Subject Re Eme g ng Mic obes & Infect ons - TEMI-2020 0121 - changes equi ed to you submiss on

Thanks, Shan fo you e fic ent ac ion!

On 2/13/20, 9 56 AM, Lu, Shan [Sh @]> w ote

You page is now accepted. Hope you have eceived the dec sion let e .

Best.

Shan

--- -O ginal Message-----
F om L u, Shan-Lu lu.6244@osu.edu>
Sent Thu sday, Feb ua y 13, 2020 8 57 AM
To @]
Cc Lu, Shan Shan.Lu@umassmed.edu> Su, Lishan l shan_su@med.unc.edu>
Subject Re Eme ging Mic obes & Infections - TEMI-2020 0121 - changes equi ed to you subm ssion
Impo tance H gh

Hi Jo gie

I have modif ed as inst ucted and at ached the new one to this ema l. Please help upload and p oceed.

Thank you.

Shan-Lu

Shan-Lu L u, M.D., Ph D.
P ofesso
Co-Di ecto , Vi uses and Eme ging Pathogens P og am Infectious Diseases Inst tute Cente fo Ret ovi us Resea ch Depa tments of Vete ina y Biosc ences, M c ob al Infect on and Immun ty, and Mic obiology The Ohio State Unive sity
1900 Co lev Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone (614) 292 8690
Fax (614) 292 6473
Ema l Lu.6244@osu.edu shan.lu.lu@osumc.edu

On 2/13/20, 8 43 AM, Eme ging Mic obes and Infec ions onbehalfo @manuscriptcentral.com> w ote

13-Feb 2020

Dea P ofesso Liu,

You above efe enced manuscript, entitled SARS-CoV-2 no evidence of a labo ato y o ig n equi es some fu the changes befo e it is eadly fo eviewing n Eme g ng Mic obes & Infec ions. You submiss on has been etu ned to you and is located in you Autho Cen e as a d aft, so that you due to these easons

1. No line numbe ng

K ndly add a l ne numbe ng in you main document.

2. Exceeded efe ence count

K ndly be info med that the efe ence count fo the commenta y a t cle should not be mo e than 15.

You submiss on along w th all files you submit ed s now n you Autho Centre , at https://u.lifelense.com/v3/__https://nam01.safelinks.protection.outlook.com/?u.l=https*3A*2F*2Fu.lifelense.com*2Fv3*2F__https*3A*2F*2Fmc.manuscriptcentral.com*2Fems__*3BlIKG6ex8YInGs1Bq8I12P-OCGs-7dBs1Hd1Qxd3rOmdbxOCNbuR_nzCdwEKJF1HkRtV45qqq!!ykdVtnw!*24&data=02*7C01*7CShan.Lu*40umassmed.edu*7C0e7fc6818f7047e0d790008d7d08c97e*7Ceef9155fe2da34478a6c4445fafa57b2e*7C0*7C0*7C637171900355158902&sdata=jfD3Q3uwBEOX gIXKqzrbb2Ak5*2FI3UA32F55n1KfmYUy8*3D&_ese_ved=0__JSU JSU JSU JSUx6JU JSU JSU JSU JCIYGIXeukYImmIJCKG7ewWhl HsCqeOeGisznxUGq7_XE JeuPxFzezrzh3pxqD9XD9bS1-_K__BK2TQE

You may contact the Edito ial O fice if you have fu the quest ons.

S nce ely,

Jo g e Lym Luna
Eme ging M c obes & Infect ons Edi o al Off ce
temi-peer ey.eye@ osu nabs.tandf.co.uk